Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sharper brain scans could spot Parkinson's before symptoms strike

NCT ID NCT07809438

Diagnosis Sponsor: Michael J. Fox Foundation for Parkinson's Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are comparing two PET cameras, a high-resolution one called NeuroEXPLORER and a standard Siemens Biograph, to see which better detects brain changes in people with prodromal Parkinson's disease. About 25 participants from an existing Parkinson's study will receive scans with both cameras after an injection of a radioactive tracer called [18F]AV-133. The scans will be repeated over two years to track how tracer uptake changes in the brain. The goal is to learn whether the high-resolution camera gives clearer or earlier signals of the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a radioactive tracer called [18F]AV-133 used with PET imaging
What this could lead to
If the high-resolution camera detects brain changes earlier or more clearly, it could improve how doctors identify Parkinson's disease before symptoms become obvious.
What could go wrong
This is a small imaging study with 25 participants, so the results may not apply to everyone. The tracer and cameras may not show meaningful differences, and the study does not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Prodromal participant enrolled in the PPMI 015 sub study. 2. Able to provide consent. Exclusion Criteria: a) Any medical or psychiatric condition or lab abnormality that precludes participation per investigators judgement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prodromal Parkinson's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prodromal Parkinson's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute for Neurodegenerative Disorders

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.